Genetic Signatures will exhibit at the 16th Asia-Pacific Congress of Clinical Microbiology and Infection (APCCMI) in Melbourne, Australia on 30 November – 3 December 2016.
Genetic Signatures will be exhibiting their EasyScreen products for the detection of infectious diseases, including kits for diagnosing bacterial, viral and protozoan causes of gastroenteritis direct from faeces, and the causes of respiratory infection from swabs in Viral Transport Media (VTM).
Visit Genetic Signatures at Booth 01 at APCCMI 2016 for more information.
About APCCMI: APPCMI is an important meeting on clinical microbiology and infectious diseases offering a unique opportunity for clinicians, scientists, researchers, pharmacists and other healthcare professionals working in the Asia Pacific region to meet international experts from various parts of the world. The programme will include presentations on antibiotic stewardship and antimicrobial resistance, infection prevention and control, public health, mycobacterial diseases, virology including HIV, hepatology, parasitology, bacteriology including diagnostics and vaccines.
About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, 3Base™. Founded in 2001 by the late Dr Geoffrey Grigg, the former Chief of Molecular Biology at CSIRO, Genetic Signatures has released a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen™ brand. MDx is a modern technique increasingly used by hospitals and pathology laboratories to detect specific sequences of the genome, the DNA or RNA that define an organism. Genetic Signatures’ proprietary MDx 3Base™ platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures’ current target markets are major hospital and pathology laboratories undertaking infectious disease screening. As the spread of infectious diseases around the world continues to grow, the Company plans to launch additional products for the detection of pathogens associated with MRSA, sexual health infections, tuberculosis, meningitis and, antibiotic resistance.